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Abstract: Due to their unique properties, Anticancer dendrimer-based drugs have been 
displaying promising results in both in vitro and in vivo in the treatment of cancerous cells, 
as compared to the traditional polymers. In this report, two conjugates (G1+Pt and G2+Pt) 
of cisplatin [cis-diaminedichloroplatinum; (CDDP)] with two generations (G1, G2) of a 
biocompatible anionic dendrimer were prepared in an aqueous media. Their potential cytotoxic 
effects, in two sensitive cancer cell lines HT1080 and CT26 together with one resistant cancer 
cell line SKOV3, using MTT (methyl thiazolyl tetrazolium) assay were examined. Hemolytic 
impacts and cell death mechanisms of the conjugates on human blood and HT1080 cell line 
were also investigated. The conjugate G2+Pt showed greater toxicity up to 9× and 2× in the 
sensitive and resistant cell lines (IC50 comparison, inhibitory concentration) respectively when 
compared to the parent drug. The G1+Pt conjugate showed greater toxicity only in the sensi-
tive HT1080 (2×) and CT26 (3.7×) cell lines. Moreover, the G1+Pt conjugate was less toxic 
approximately one third of the cisplatin in SKOV3 after 48 hrs of incubation. In summary, the 
G2+Pt conjugate had greater toxicity than the G1+Pt conjugate and cisplatin, based on the 
in vitro results. Approximately the same hemolysis behavior was observed for both conjugates 
and cisplatin. Both apoptosis and necrosis mechanisms (about 2× more than cisplatin) were 
attributed to conjugates and cisplatin in a direct correlation between the concentration and the 
degree of cell death. In conclusion, these conjugates with such high potency and minimum 
hemolysis would be suitable candidates for use against these cancerous cell lines as efficient 
and novel antitumor agents.
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Introduction
Macromolecular prodrugs, especially polymer-drug conjugates, which were first 
proposed by Ringsdorf in the mid 1970s, are the foundation for new types of anti-
cancer entities.1 Soon after this, very promising antitumor activities (eg, due to the 
alteration of parent drug pharmacokinetics/pharmacodynamics) were demonstrated 
for these structures in preclinical and clinical study phases.2 Conventionally, hydro-
philic, linear and branched bio- or nonbiodegradable polymers such as natural poly-
mers; the linear polymers of amidoamines, or N-(2-Hydroxypropyl) methacrylamide 
(HPMA)-copolymers have been utilized as carriers for anticancer agents. However, 
these polymers have shown some drawbacks, eg, unpredictable and uncontrollable 
pharmacokinetic/pharmacodynamic behaviors due to their inherently high polydis-
persity index which are due to the heterogeneous products formed.3 Today, polymeric 
structures with very low polydispersity, eg dendrimers, are being preferred as carriers International Journal of Nanomedicine 2010:5 64
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of antitumor drugs. Dendrimers are a series of polymeric 
architectures with different chemical and surface-related prop-
erties. In comparison to traditional polymers, dendrimers have 
been claimed to be superior due to their nanoscale (nanometer-
sized polymers) architecture, narrow polydispersity index, 
and the large number of surface reactive/functional sites with 
the potentiality for bond formation with therapeutics.4
Yet, not all of the dendrimers are suitable in this respect; 
biocompatible properties like aqueous solubility, biodegra-
dation, low cytotoxicity and nonimmunogenicity properties 
must be verified for them both in vitro and in vivo.5 One vari-
ant of these macromolecular prodrugs that has been partially 
investigated is the dendrimer cisplatin conjugates.6 Encourag-
ing outcomes in the treatment of various kinds of cancer cells 
have been reported for these compounds.7 However, one major 
problem associated with these drug conjugates is the toxic-
ity of the dendrimers themselves. This toxicity is dependant 
upon the physico-chemical properties of the dendrimers.5 
Research and development of dendrimer-based antineoplastic 
prodrugs can be accelerated with the use of biologically safe 
dendrimers, as carriers for conventional anticancer drugs. This 
is especially pertinent for cancers with drug resistance eg, 
as a consequence of the reduction in drug uptake. Cisplatin, 
an anticancer drug (cis-diamminedichloroplatinum with a 
molecular weight of 300.04 Da) used extensively in the treat-
ment of many cancers such as ovarian, head, neck, testicular, 
and small cell lung carcinoma was chosen as a model drug to 
study its physicochemical interactions with the dendrimers.8 
The disadvantages of low aqueous solubility, high protein 
binding that reduce drug potencies, together with the non-
specific or systemic toxicity (eg, nephrotoxicity) and both 
inherent/or acquired resisitences in many types of treatments 
have been reported for platinum-derived drugs.9,10 Thus, our 
objective for studying these dendrimer-Pt conjugates was to 
increase the anticancer potency of cisplatin by increasing 
its water solubility, decreasing its protein binding, and also 
reduction its nephrotoxicity with a view to their clinical use. 
It is postulated that these advantages could be gained by dis-
placing the transient, easily alterable chemical agents of cis-
platin (ie, chloride ions) with groups such as carboxylate ions 
on the dendrimer surfaces, so as to form more stable bonds 
(due to greater thermodynamic stability, steric effects, and 
ring stability of carboxylate ions versus the chloride ions) with 
cisplatin and prevent nonspecific and undesirable reactions 
with strong nucleophilic groups (eg, thiols present in plasma 
proteins or membrane walls of kidney cells) resulting from 
cisplatin’s poor water-stability prior to reaching their sites 
of actions.11–14 Increasing the stability of these bonds would 
preclude undesirable protein binding and systemic toxicities 
that are associated with cisplatin therapy.
Using citric acid in the synthesis of these dendrimers, it 
was hoped that the conjugates thus formed would be able to 
overcome the reduced uptake of cisplatin in cell lines with 
intrinsic and/or acquired resistances. It was hypothesized that 
this could be achieved by sequestering cisplatin (ie, mask-
ing via the linkage process) and supplying the cell’s energy 
needs with the citric acid (a key component in the synthesis 
of adenosine triphosphate), utilized in the synthesis of the 
dendrimers. It was hoped that, dendrimers synthesized in 
this way can carry the drug into the cells without any inter-
vention of the resistance mechanisms. So, two generations 
of anionic, water-soluble, linear-globular dendrimers G1 
(MW∼1000 Da) and G2 (MW∼2000 Da), where poly ethylene 
glycol (PEG) is the core and citric acid is the periphery, were 
selected for the subsequent couplings with cisplatin.
These dendrimers had been synthesized before by Namazi 
and colleagues.15,16 and in our previous studies any in vitro 
cytotoxicity, immunogenicity, and hemotoxicity were not 
observed up to the concentration of 0.5 mg/mL (Alavidjeh 
and colleagues.unpublished data). First, In this study, surface 
conjugations and surface properties of the dendrimers (eg, 
size and zeta potential distribution) as a result of the reaction 
with cisplatin were examined using Fourier transform infrared 
(FT-IR) spectroscopy and dynamic light scattering (DLS ) 
technique. The reaction kinetics of cisplatin in the absence 
and presence of the dendrimers was investigated by measuring 
the chloride ions released using an ion selective electrode. The 
amount of drug loading on each of the conjugates was deter-
mined by atomic absorption spectroscopy (AAS). The in vitro 
release of cisplatin was examined in a two buffer media with 
two pHs of 7.4 and 5.4, simulating the conditions of plasma 
and secondary lysosomes, for 72 hours to estimate the stabil-
ity and strength of the conjugates under those conditions. The 
in vitro cytotoxic potential of the conjugates was examined 
using sensitive cell lines HT1080, CT26 and a partially 
resistant cell line SKOV3. The hemolytic behavior of each of 
the conjugates was examined at different concentrations and 
a variety of durations to to assess the hemotoxicity of these 
compounds versus free cisplatin. Finally the mechanisms of 
cell death induced by the conjugates and free cisplatin, in 
two different concentrations, were studied by flow cytometry 
method as these mechanisms are considered important in the 
final outcome of cancer therapy.17 In summary, the results of 
these studies would be able to assist in the primary screening 
of more potent macromolecular prodrugs with less systemic 
side effects.International Journal of Nanomedicine 2010:5 65
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Materials and methods
Materials
The dendrimers (G1, [1000 Da] and G2, [2000 Da]) had 
previously been prepared by the method of Namazi and 
colleagues.15,16 Cisplatin (II) (MW 300.4 Da) and methyl thia-
zolyl tetrazolium (MTT) powder were purchased from Sigma-
Aldrich, (Sigma-Aldrich Inc, St. Louis, MO, USA). Dialysis 
bag (molecular weight cut-off, 100–500 Da) was purchased 
from Spectrumlabs (Spectra/por®, Rancho Dominguez, CA, 
USA). Cell lines HT1080 (Human fibrosarcoma, ATCC, 
CCL-121), SKOV3 (Human ovarian, NCBI code; C209), 
CT26 (fibroblast, NCBI code; C532) were purchased from 
The Pasteur Institiute (Tehran, Iran), and AnnexinV-PI kit was 
obtained from Roche (Roche company, AnnexinV-FLUOS®, 
Basel, Switzerland).
Preparation of the cisplatin derivatives
The dendrimers with carboxylate end groups were reacted 
with cisplatin in two different molar ratios ie, 1:2 and 1:3. 
Typically, 180 mg of cisplatin (6 × 10–4 mole) and the den-
drimers, G1 (2–3 × 10–4 mole), G2 (2–3 × 10–4 mole), were 
dissolved in 120 mL and 60 mL of double deionized water 
(D.D.W) separately for each of the reactions. Each dendrimer 
solution was then partially neutralized using 0.01 M NaOH 
solution, to provide the nucleophilic carboxylate end groups, 
and then freeze-dried for subsequent reactions with cispla-
tin. The dendrimer solutions, in different molar ratios, were 
added dropwise to the cisplatin solution with constant mild 
stirring. The stirring was continued, in the dark, for 18 hours. 
At the end of the reaction the mixtures were transferred to 
a dialysis bag and dialyzed against D.D.W for 72 hours to 
separate the unreacted cisplatin from the formed conjugates. 
A sample from the filtrate was transferred to a TLC plate 
and tested for the absence of cisplatin as mentioned in the 
USPXXIV Pharmacopea (developer: acetone and 1M nitric 
acid (90:10); spray reagents: stannous chloride, hydrogen 
chloride, and potassium iodide). When no platinum release 
was observed after 72 hrs, the samples inside the dialysis 
bag were lyophilized and kept at -20 °C for further analy-
ses. The schematic structural diagrams of the dendrimers, 
cisplatin, and the possible formed conjugates were depicted 
in Figure 1.
chloride release
In order to have a comparison between the kinetics of the 
reaction of cisplatin with or without the dendrimers in 
the reaction media, the rate of chloride release was mea-
sured from cisplatin in both the absence and presence of 
the dendrimers in D.D.W using an ion selective electrode 
(Metrohm®, Oberdorfstrasse, Switzerland).
Drug loading
The drug loading range was determined by atomic absorption 
spectroscopy (AAS) method (SpectrAA240, Varian Inc, Palo 
Alto, CA, USA) for each of the derivatives in two different 
molar ratios.
Platinum release
The dendrimer-Pt conjugates (10 mg/mL) were each dis-
solved in two different Sorenson´s buffers pH 7.4 and 5.4, to 
simulate the physiological media. The resultant samples were 
then dialyzed against the same buffers, at 37 °C for 72 hrs. 
After each time interval a sample was taken to determine the 
platinum content of the conjugates by the AAS method.
size and zeta potential distribution
Each of the dendrimers and conjugates (0.5 mg/mL) was 
checked for any changes in the size and zeta potential 
distribution before and after the reaction with the cisplatin by 
DLS technique (Malvern, Zetasizer Nano ZS, Worcestershire, 
UK) in D.D.W.
FT-IR studies
The spectral changes of the dendrimers were examined by 
Fourier transform infrared (FTIR) spectroscopy (Thermo-
Nicolet, NEXUS 870, Waltham, MA, USA) before and after 
the conjugation. Through changes in the wavenumbers of the 
functional groups in the IR spectra, we were able to show the 
surface conjugation and clarify which groups were involved 
in the conjugation process.
In vitro toxicity assay
MTT assay is one the current techniques which is widely used 
for cell viability measurement. This assay is based on the 
reduction of MTT to formazan by viable cells.18,19 At the 
end of the incubation times (24, 48 hrs) with various con-
centrations of the conjugates (0.787, 1.575, 3.15, 6.3 µg/mL; 
equivalent to free cisplatin) and pristine cisplatin, the super-
natants of the cells (HT1080, SKOV3, CT26) were removed. 
MTT solution was added to each well of the plates to give 
the final concentration of 0.5 mg/mL, and the cells were 
incubated for an additional 4 hours. Thereafter, the solu-
tions were removed, and the dye was dissolved in 100 µl 
dimethyl sulfoxide; the plates were kept in a dark place for 
another one hour in order to be ready for spectrophotometric 
determination. The amount of absorption in each well; that is, International Journal of Nanomedicine 2010:5 66
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Figure 1 schematic diagrams of cisplatin (cDDP), the dendrimers g1, g2 and their possible reactions (generation of different conjugates) in aqueous media.
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the conversion of MTT to formazan by metabolically viable 
cells, was calculated by an automated microplate reader at 
570 nm. The results were devided to the absorption of the 
untreated control culture and expressed as percentage of 
viable cells.
Hemolysis assay
Blood samples were taken from un-medicated volunteers 
(anti-coagulated samples). The final hematocrit fraction was 
obtained after centrifuging the whole blood at 1000 rpm 
for 5 min, and discarding the supernatant. The cells were 
then rinsed three times with cold phosphate buffered saline 
(PBS 5% v/v). The conjugates and free cisplatin were then 
dissolved in PBS and incubated and shaken at 37 °C and 
50 rpm respectively for two hours with the blood sample 
mixtures, composed of 1:5 v/v conjugate solutions to blood 
to make the final, specified concentrations of the conjugates 
and cisplatin (1.575, 3.15, 6.3 µg/mL weight equivalent to 
free cisplatin). Following this the mixture was centrifuged 
at 1000 rpm for 5 min and the supernatants removed and 
analysed using a spectrophotometer at 413 nm. The results 
were then compared to the positive control (0.1% v/v Triton-
X100 in PBS) which produces 100% hemolysis and negative 
control which contained only a mixture of blood and PBS as 
an indicator for the minimum hemoglobin release.19,20
Apoptosis-necrosis assay
Apoptotic and necrotic cells were identified by an AnnexinV-PI 
Staining Kit. Apoptosis and necrosis have been considered as 
the two different mechanisms of the cell death. By this tech-
nique, we are able to measure and differentiate between these 
two mechanisms.19,21 Following the incubation for 24 hours 
with two different concentrations of the G1+Pt, G2+Pt and 
free cisplatin (0.75 and 1.5 µg/mL, the weight equivalent to 
cisplatin) with the HT1080 Cells, and they were washed three 
times with PBS, trypsinized, and transferred to a new tube. International Journal of Nanomedicine 2010:5 67
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Following this the cells were centrifuged at 200 × g for 
5 minutes, stained using trypan blue and then counted using 
a hemocytometer, Approximately 106 cells were analyzed for 
each flow cytometry run. The cells, both treated and untreated 
ones, were then incubated with the AnnexinV-PI (propidium 
iodide) reagent buffer for 15 minutes at room temperature. 
Following the incubation the samples were diluted with 
500 µL of the incubation buffer for flow cytometry analysis. 
The percentage of the treated apoptotic and necrotic cells 
versus the untreated control cells was identified by the flow 
cytometry (Partec, GmbH Munster, Germany) method with 
Flomax software (version 2.4) at suitable excitation (488 nm) 
and emission wavelengths (518 nm) for Annexin-V detection 
and a band pass filter greater than 600 nm for propidium iodide 
(PI) detection according to the suggested protocol in the kit for 
FITC-PI detection.
statistical analysis
All the experiments were conducted in triplicate and the 
results were compared using one-way ANOVA for mean 
comparison of more than two groups with SPSSsoftware.11 
Results were reported as significant for P  0.05.
Results
chloride release
The rate of chloride ion release from the cisplatin in the pres-
ence of the dendrimers in aqueous media showed a higher 
(×2) and approximately the same as the free cisplatin in the 
absence of the dendrimers at 18 hrs after the beginning of the 
reaction (Figure 2). Therefore, it was concluded that the rate 
of the reaction (chloride release) with cisplatin in the aqueous 
media containing the dendrimers was higher than in the aque-
ous media without the dendrimers. This may result from the 
contribution of the carboxylate ions together with the water 
molecules in displacing of the chloride ions from cisplatin.
Drug loading
Almost the same amount of drug loading (∼6% weight of 
platinum/weight of the conjugates) was gained for each of the 
dendrimers irrespective of their generations and molar ratios 
(Table 1). This might result from the fact that the effect of the 
more  functional groups in the G2 can be neutralized by  its 
more associated steric repulsion in comparison with the G1.
In vitro release of platinum
The amount of platinum release from the two conjugates at 
differing pHs (pH 7.4 and pH 5.4 were selected in order to 
mimic the physiological media existing in the plasma and 
secondary lysosomes, respectively) showed both a time and 
concentration dependent behavior. According to the release 
amounts, the G2+Pt was a little more stable (less than 3%) 
than the G1+Pt. On the whole, the release rate in the acidic 
pH (5.4) was slightly greater and faster (about 2%) than the 
neutral pH (7.4) for both conjugates. This phenomenon can be 
explained due to the catalytic effect of the acidic conditions 
on the ease of displacement of water molecules with chloride 
or carboxylate ions inside the cisplatin cavity. This reduction 
in the release rate of cisplatin in neutral condition (pH 7.4) 
is very important in preserving a stable bond until reaching 
the target site (tumor) and therefore prevent unwanted and 
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Figure 2 The comparative release of chloride ions from cisplatin (cDDP) alone and in reaction with the dendrimers g1 and g2. International Journal of Nanomedicine 2010:5 68
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nonspecific toxicities resulting from out of place cisplatin 
release in the blood circulation. On the whole, the maximum 
released amount of platinum (approximately 8% of the total) 
was observed in the conjugate G1+Pt at pH 5.4 (Figure 3).
size and zeta potential distribution
As can be observed from Table 2, when the conjugates were 
formed from the dendrimers, an increase in the size/poly dis-
persity and a decrease (negative charge) in the zeta potential 
were seen in the conjugates as contrasted with the dendrimers. 
The difference in the size was more marked (∼3×) in the 
G1+Pt conjugate, while the variance in the zeta potential 
distribution was more drastic (∼3×) in G2+Pt conjugate. This 
may result from the more negative groups being available 
at its surface. These phenomena can result from the cross-
linking of the dendrimers with cisplatin which intercalates 
between two of the dendrimer molecules and also masks the 
negative charges (due to carboxylate ions) of the dendrimers 
for the reaction with cisplatin, respectively.22
FT-IR studies
In addition to typical peak characteristics of chemical 
structures of the dendrimers, FT-IR spectra of the con-
jugate products showed distinct alterations in the spectra 
(Figure 4) indicating the conjugation at the dendrimer 
surfaces via carboxylate groups. For example, the marked 
increase in the ∼31 cm–1 wavenumber of IR spectra of the 
G1 from 1577.81 cm–1 (assignable to asymmetric stretching 
of –COO–) to 1608.53 cm–1 for the G1+Pt may have resulted 
from the reaction of oxygen (as a strong base) of the carbox-
ylate (–COO–) ion with platinum (as a weak Lewis acid).
This type of bond polarizes, deshields the carbon atom of 
the –COO– group, this induces a small positive charge on it, 
and consequently increases the possibility of the carbonyl 
group having a greater strength and wavenumber. Such an 
increment (about 25 cm–1) was also observed in the G2, a 
shift from 1593.17 cm–1, related to asymmetric stretching of 
the –COO– group of the G2, to 1618.87 cm–1 for the G2+Pt. 
Moreover, the appearance a doublet bands near 3283 cm–1 
and 3247 cm–1 for each of the G1+Pt and G2+Pt conjugates 
in comparison with the G1 and G2 dendrimers that is related 
to the stretching of the N-H groups of cisplatin.
In vitro cytotoxicity assay
As can be seen from Figure 5, the G2+Pt conjugate was 
more toxic than the parent cisplatin in all cell lines, 
times, and concentration range. The cytotoxic strength 
of some conjugates like G2+Pt based on IC50 calculation 
(the concentration which inhibits 50% growth against the 
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Abbreviation: h, hours.
Table 1 The weight percent of platinum in the conjugates at 
different ratios of the dendrimers to cisplatin
Pt derivatives Dedrimers:  
Pt (CDDP) Ratios
Pt content  
in wt % (mean ± SE) 
AAS method (flame)
g1+Pt 1:2 5 ± 0.21
g1+Pt 1:3 6 ± 0.33
g2+Pt 1:2 6 ± 0.21
g2+Pt 1:3 7 ± 0.15International Journal of Nanomedicine 2010:5 69
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Table 2 size and zeta potential distributions of the dendrimers and their related conjugates after reaction with cisplatin (cDDP)
Types of the dendrimers 
and their derivatives
Size distribution,  
mean(nm) ± width
Zeta potential (mv) ± width
g1 225 ± 32.6 (100%) -17.6 ± 9.68 (100%)
g1+Pt 710 ± 540 (94.5%); 4320 ± 873 (5.5%)  -16.4 ± 5.16 (100%)
g2 85.1 ± 11 (100%) -67 ± 9.70 (78.5%);  -41 ± 2.62 (8.1%);  -7.4 ± 4.38 (8%)
g2+Pt 141 ± 47.3 (100%) -20.9 ± 4.24 (85.2%);  -6.58 ± 1.42 (14.8%)
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Figure 4 FT-IR spectra of the dendrimers before and after the reaction with cisplatin (cDDP). IR: (A) g1, (B) g1+Pt, (C) g2, (D) g2+Pt.
Abbreviations: FTIR, Fourier transform infrared; IR, infra-red.
maximum amount) with nonlinear regression (GraphPad,® 
version 4) was 9 × greater in HT1080 (24 hrs) and CT26 
(48 hrs) cell lines in comparison with free cisplatin while 
the conjugate G1+Pt showed a higher maximum toxicity 
of 3.7 × in CT26 cell line in comparison with the cisplatin 
after 48 hrs of incubation. In addition, the G1+Pt showed 
less toxicity in SKOV3 cell line increased to one third of 
free cisplatin after 48 hrs of incubation, while the same 
potency was observed for SKOV3 and free cisplatin after 
24 hrs of incubation. The G1+Pt also showed less toxicity 
in CT26 cell line after 24 hrs of incubation. The IC50 values 
are displayed in Figure 6.International Journal of Nanomedicine 2010:5 70
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Hemolysis assay
Based on the results gained from the hemoglobin release 
from the erythrocytes, only the G2+Pt conjugate at the 
concentration of 6 µg/mL showed a slightly more hemo-
globin release about 1.5 × in comparison with the nega-
tive control (P  0.05). The rest of the conjugates did not 
show any statistical difference (P  0.05) against the 
negative control over the concentration range. Favourable 
hemocompatibility was found for these conjugates similar 
to cisplatin (Figure 7).
Apoptosis-necrosis assay
Apoptosis-necrosis assay was carried out at two moder-
ately toxic concentrations (0.75 and 1.5 µg/mL) in order International Journal of Nanomedicine 2010:5 71
Dendrimer-cis-platinum (II) conjugates against cancer cell lines Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to determine and differentiate between the two cell death 
mechanisms induced by the conjugates and free cisplatin. 
These death mechanisms are considered crucial in determin-
ing the final treatment, eradication, and recurrence of the 
tumor cells.23 From the results, a direct correlation between the 
concentration and cell death was observed for the derivatives 
and free cisplatin; ie, the higher the concentration the greater 
the degree of cell death. Greater toxicity was observed for the 
G2+Pt complex, and increased necrosis was also seen for this 
conjugate. Generally, the amount of apoptosis and necrosis, 
was higher nearly 8%, (∼2×) for the conjugates than those of 
cisplatin. The detailed results are presented in the Figure 8.
Figure 5 Viability of the different cancer cell lines according to the mitochondrial activity of the cells incubating with different kinds of Pt derivatives and free cisplatin (cDDP) 
after 24 and 48 hrs. (A) HT1080 cell line, (B) cT26 cell line, (c) sKOV3.
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Figure 7 In vitro release of hemoglobin from human erythrocytes in contact with various concentrations of free cisplatin (cDDP) and Pt derivatives after 2 hrs of 
incubation.
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Discussion
In spite of using many kinds of polymers (traditional or 
nontraditional types) as drug carriers in the conjugation 
technique, only a small number of them have shown 
in vitro toxicity.24 The ultimate cytotoxic actions of many 
types of these conjugates are met when they are used 
in vivo as an example the polymer-drug conjugates are very 
stable and not able to release the specified drug when they 
are inside the tumor cell environment for their final action.25 
In this study we have shown the synergistic toxic effect of the 
anionic linear-globular dendrimers (with terminal citric acid 
groups) conjugated to the surface of cisplatin. This action 
resulted in the more aqueous solubility of the conjugates as 
compared to the parent drug. The dendrimers themselves did 
not show any significant toxicity at the concentrations range 
used. These observations based on in vitro cytotoxicity (IC50 
comparison) displayed that the G2+Pt conjugate showed 
a drastic increase in cytotoxicity in the sensitive cell line 
HT1080 (up to 8.4× and greater after 48 hrs) and CT26 (up 
to 9 × after 48 hrs) at all concentrations and exposure times 
used. Additionally continued toxicity was observed in these 
cell lines after 48 hrs of incubation. Such increased toxicity 
can be explained by a greater uptake of the conjugates as 
contrasted with the free cisplatin due to the citric acid content 
of the conjugates together with the greater demands of cancer 
cells for such energy sources during the time of incubation. 
The increased liberation of the drug may be attributed to 
lysosomal enzymes existing inside the cell which gradually 
breakdown the bond between cisplatin and the dendrimers. 
Similar reasons have been proposed for other polymer-drug 
conjugates thus far.24 The G2+Pt showed greater toxicity ∼2× 
as compared to the free cisplatin in the moderately resistant 
SKOV3 cell line. One of the possible resistance mechanisms 
of this cell line follows from the reduced uptake of cispla-
tin.26 The G1+Pt conjugate showed an approximately a three 
fold increase in toxicity in the sensitive cell line HT1080. 
A similar behavior was observed for CT26 cell line only after 
48 hrs of incubation (an increment of 3.7×) and much less 
toxicity was seen in this cell line after only 24 hr incubation 
time. This trend of increase in toxicity over time in the CT26 
cell line can be explained by similar reasons to those men-
tioned above, ie, the gradual uptake and subsequent liberation 
of the drug due to action of enzymes inside the cell.
The G1+Pt displayed no toxicity in inherently resistant 
SKOV3 cell line as compared to free cisplatin. There was even 
a reduction (1/3 of the parent cisplatin) in toxicity observed 
for the G1+Pt conjugate after 48 hrs when compared to the 
24 hrs incubation. A similar potency profile was observed 
for the G1+Pt conjugate to cisplatin at 24 hrs of incubation. 
This may suggest that hitherto unknown compensatory 
mechanisms could neutralize the synergistic effect of the 
conjugate during the time.
In general, the G2+Pt conjugate was more toxic than the 
G1+Pt conjugate. This might possibly be related to the higher 
citric acid content in the G2+Pt conjugate and consequently 
easier for the tumoric cells to access this for the supply of 
energy which is a prerequisite for growth.27 The smaller and 
narrower the size distribution (ie, less aggregation behavior) of International Journal of Nanomedicine 2010:5 73
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the G2+Pt conjugate may allow easier recognition and entry to 
the cell without requiring extra energy. In addition, this greater 
negative charge of the G2+Pt provides an increased number of 
sites being able to interact with the positively charged com-
ponents of the cell membrane in comparison with the G1+Pt. 
This causes the G2+Pt conjugate to penetrate the cell more 
easily at an increased rate this could be another factor contribut-
ing to the increased cytotoxicity of the G2+Pt conjugate.
The hemolysis assay was used as a test for the interac-
tion of compounds with the erythrocytes. Regarding the 
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results, exactly the same hemolysis behavior was observed 
for all the conjugates except for the G2+Pt complex at the 
concentration of 6 µg/mL. This concentration showed an 
increment in the hemolysis only ∼1.5 × against the nega-
tive control. Although relatively good hemocompatibility 
for the conjugates, complementary hemocompatibility was 
observed tests should be performed for better understand-
ing of the hemotoxicity behaviors of these conjugates. 
With hemolysis results such as these there is little chance 
of clot formation which might continue in the blood cir-
culation when using these conjugates in vivo eg, in the 
parenteral form.
Based on the results of the apoptosis-necrosis assays, 
both of the mechanisms are attributed to cell death, and a 
concentration dependency was observed for cisplatin and 
its derivatives. Also, greater toxicity (the percentage of 
apoptosis and necrosis ∼1.5×) was observed for the conju-
gates as compared to the parent cisplatin. Overall, the mode 
of cell death is very important in cancer therapy as most of 
the resistances which are observed in cancer cell lines are 
due to apoptotic-related cell death.28 The immunostimula-
tory impact of the products originating from necrotic cells 
may stimulate a macrophage-mediated antitumor response 
(contrary to apoptosis) and may produce an effective immune 
response by dendritic cells which must also be considered 
in the final therapeutic outcomes of antitumor drugs.29,30 
Therefore, it seems possible that necrotic cell death could 
be more effective than apoptosis in cancer therapy. Certainly, 
it would be reasonable to consider the bi-lateral effects of 
necrosis in being an effective cancer treatment and the more 
accomapnied unwanted inflammatory reactions which may 
aggravate clinical tolerances to these drugs in patients during 
the treatment period. Thus, a balance must be made between 
the two processes of cell death. With respect to the greater 
potencies according to the more apoptosis-necrosis observed 
for the G2+Pt and the G1+Pt complexes compared to those 
of cisplatin, these compounds seem to be able to meet the 
necessary prerequisites for being good antitumor candidates 
against the cancer cell lines tested.
Conclusion
Regarding the conjugates of cisplatin tested during this study 
and the in vitro results gained for their cytotoxicity, hemoto-
toxicity, and nontoxicity of the dendrimers, it is hoped that 
these conjugates would be able to maintain the observed 
potency in vivo and retain the parent drug conjugated at the 
surface of the dendrimers in the physiologic plasma condi-
tion. This property can prohibit the unwanted release of free 
platinum before reaching the target site ie, tumor cells; to 
prevent the undesirable systemic toxicity, preclude excessive 
plasma protein binding with cisplatin, and ultimately exhibit 
a more repeatable, reproducible, and successful treatment in 
comparison with treating a patient with free cisplatin. Such 
drawbacks have been considered to be the main causes of 
the resistance mechanisms of cisplatin.10 Furthermore, the 
conjugates, especially the G2+Pt conjugate, exhibited more 
cytotoxic potential in comparison with the parent drug in 
most of sensitive and resistant cell lines. Therefore, less 
of the conjugated parent drug would be required to obtain 
a similar therapeutic effect when compared with cisplatin 
treatment alone. It would therefore follow that such treatment 
could be attained with reduced systemic toxicity which is 
usually seen with this traditional antitumor agent. In brief, 
future in vivo studies will be able to clarify the potentiality 
of these entities in the cure of both sensitive and resistant 
cancerous cells.
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